Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545673 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7871724 | 0.84 | CYP11B1 (0.50) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL7694625 | 0.84 | RARB (0.44) | CYP4F2CYP4A11HTTTSHR | |
| SCHEMBL2302020 | 0.83 | KDM4E (0.47) | CYP4F2CYP4A11CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29410056 | 0.83 | KDM4E (0.47) | CYP4F2CYP4A11CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL17471653 | 0.83 | CYP1A2 (0.38) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL604198 | 0.82 | CYP1A2 (0.51) | CYP4F2CYP4A11CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16922694 | 0.81 | KDM1A (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL17295280 | 0.79 | CA2 (0.42) | CYP4F2CYP4A11CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12533678 | 0.79 | KDM1A (0.38) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4048279-B1 | 2-(2,6-DIOXOPIPERIDIN-3YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1. 3-DIONE FOR USE IN TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | CELGENE CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3952880-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE FOR USE IN THE TREATMENT OF NON-HODGKIN LYMPHOMA | CELGENE CORP (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4568955-A1 | ANTIBACTERIAL COMPOUNDS | Blacksmith Medicines, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119907795-A | Antibacterial compounds | 布莱克史密斯医药公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250084067-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-03-13 | — | — | US | disclosed |
| EP-4516786-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| EP-1091736-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000034239-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000001382-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | CYP4F2 440/4885CYP4A11 140/4885CYP1A2 577/4885 |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 | CYP4F2 2795/4885CYP4A11 2277/4885CYP1A2 2041/4885 |
| US-20250084067-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CYP51A1, CYP11B2, CYP11B1 | CYP4F2 25/4885CYP4A11 8/4885CYP1A2 22/4885 |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CYP51A1, CYP11B2, CYP11B1 | CYP4F2 25/4885CYP4A11 8/4885CYP1A2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.